Grace Therapeutics
GRCE
24 hedge funds and large institutions have $258K invested in Grace Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 7 reducing their positions, and 6 closing their positions.
0.04% less ownership
Funds ownership: 0.06% → 0.03% (-0.04%)
4% less funds holding
Funds holding: 25 → 24 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
80% less capital invested
Capital invested by funds: $1.32M → $258K (-$1.07M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.1K |
| 2 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$13.5K |
| 3 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
+$9.06K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$8.46K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$452K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$99K |
| 3 |
VF
Virtu Financial
New York
|
-$63.9K |
| 4 |
Two Sigma Advisers
New York
|
-$43.6K |
| 5 |
JLBC
J.L. Bainbridge & Co
Sarasota,
Florida
|
-$30K |
GRCE Hedge Fund Activity: Q3 2020 in Review
24 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2020, worth a combined $258K — down 80% from $1.32M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GRCE and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 0 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $33.1K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $452K sold.
- 24 institutional investors held Grace Therapeutics (GRCE) as of Q3 2020, down from 25 in Q2 2020.
- Funds reported $258K of Grace Therapeutics stock for Q3 2020, down 80% quarter-over-quarter.
- 5 funds opened new Grace Therapeutics positions in Q3 2020 and 6 closed out, a net change of -1 holder.
- The largest Grace Therapeutics buyer in Q3 2020 was Susquehanna International Group, an estimated $33.1K added.
- The largest Grace Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $452K sold.
Based on aggregated 13F filings for Q3 2020.